Skip to content
    Reviews

    Precision Medicine in Genitourinary Cancers

    Katrina Collins and Liang ChengExpert review of anticancer therapy

    Precision Medicine in Genitourinary Cancers
    A comprehensive review of literature from January 2016 through October 2026 outlines the variable maturity and clinical utility of molecular profiling across genitourinary malignancies, including prostate, urothelial, renal, and testicular cancers.
    In prostate cancer, molecular profiling and germline testing inform both treatment selection—such as homologous recombination repair (HRR) testing for PARP inhibitor therapy—and hereditary-risk assessment, alongside prostate-specific membrane antigen (PSMA) theranostics. In urothelial carcinoma, molecular profiling actively guides management through FGFR3-targeted therapies and circulating tumor DNA (ctDNA)-guided adjuvant immunotherapy, whereas germline testing remains selective and largely restricted to hereditary-risk evaluation.
    Conversely, precision oncology applications in renal cell carcinoma and testicular cancer face distinct limitations. In renal cell carcinoma, PD-L1 status and tumor mutational burden (TMB) remain non-predictive, transcriptomic signatures are investigational, and germline evaluation is selective, primarily identifying hereditary risk and guiding syndrome-directed treatment in von Hippel-Lindau disease alongside HIF-2α-directed therapy. In testicular cancer, germline testing has no established clinical role; although investigational serum miR-371a-3p outperforms conventional serum tumor markers diagnostically, it cannot detect teratoma, and its overall clinical utility remains unvalidated.

    Key Takeaways

    • Molecular profiling currently guides clinical management in prostate cancer (via homologous recombination repair testing, germline assessment, PARP inhibition, and PSMA theranostics) and urothelial carcinoma (via FGFR3-targeted therapy and ctDNA-guided adjuvant immunotherapy).
    • In renal cell carcinoma, PD-L1 expression and tumor mutational burden remain non-predictive, transcriptomic signatures remain investigational, and germline evaluation is selective, primarily directing therapy in von Hippel-Lindau disease alongside HIF-2α-directed treatments.
    • In testicular cancer, investigational serum miR-371a-3p diagnostically outperforms conventional serum markers but cannot detect teratoma, leaving its clinical utility unvalidated and germline testing without an established role.
    Read the original sourceExpert review of anticancer therapy